Targovax granted European Patent for ONCOS-102 in combination with chemotherapy
Patent protection of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma in Europe Oslo, 24 September 2021: Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889. The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. Torbjørn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this EU patent has been granted, further